• Simon S. Lo
  • Bin S. Teh
  • Jiade J. Lu
  • Tracey E. Schefter
Part of the Medical Radiology book series (MEDRAD)


Stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR) entails the precise and focused delivery of a small number of fractions of radiation in the ablative dose range to extracranial targets. Advances in technologies have facilitated safe and effective delivery of SBRT/SABR to various organ sites. The clinical experience with the use of SBRT/SABR to treat various extracranial organ sites has exponentially increased in the past 5–10 years in North America, Europe, and Asia. This chapter provides an introductory overview on various aspects of SBRT/SABR.


Intensity Modulate Radiation Therapy Stereotactic Body Radiation Therapy Clonogenic Cell Internal Target Volume Intensity Modulate Radiation Therapy Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Blomgren H, Lax I, Naslund I, Svanstrom R (1995) Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 34(6):861–870PubMedCrossRefGoogle Scholar
  2. Cardenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 12(3):218–225PubMedCrossRefGoogle Scholar
  3. Chang BK, Timmerman RD (2007) Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol 30(6):637–644PubMedCrossRefGoogle Scholar
  4. Chang EL, Shiu AS, Mendel E, Mathews LA, Mahajan A, Allen PK, Weinberg JS, Brown BW, Wang XS, Woo SY, Cleeland C, Maor MH, Rhines LD (2007) Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 7(2):151–160PubMedCrossRefGoogle Scholar
  5. Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, Kreisel D, Patterson GA, Bradley JD (2010) Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 140(2):377–386. S0022-5223(10)00261-8[pii], doi: 10.1016/j.jtcvs.2009.12.054 Google Scholar
  6. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter TE, Kavanagh BD, Larner JM (2010) Chest wall volume receiving >30 gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76(3):796–801PubMedCrossRefGoogle Scholar
  7. Forquer JA, Fakiris AJ, McGarry RC, Cheung MK, Watson C, Harkenrider M, Henderson MA, Lo SS (2009a) Treatment options for stage I non-small-cell lung carcinoma patients not suitable for lobectomy. Expert Rev Anticancer Ther 9(10):1443–1453. doi: 10.1586/era.09.117 CrossRefGoogle Scholar
  8. Forquer JA, Fakiris AJ, Timmerman RD, Lo SS, Perkins SM, McGarry RC, Johnstone PA (2009b) Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 93(3):408–413CrossRefGoogle Scholar
  9. Fuks Z, Kolesnick R (2005) Engaging the vascular component of the tumor response. Cancer Cell 8(2):89–91PubMedCrossRefGoogle Scholar
  10. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, Wloch J, Ye H, Kestin LL (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28(6):928–935. JCO.2009.25.0928[pii], doi: 10.1200/JCO.2009.25.0928 Google Scholar
  11. Hamilton AJ, Lulu BA, Fosmire H, Stea B, Cassady JR (1995) Preliminary clinical experience with linear accelerator-based spinal stereotactic radiosurgery. Neurosurgery 36(2):311–319PubMedCrossRefGoogle Scholar
  12. Hoppe BS, Laser B, Kowalski AV, Fontenla SC, Pena-Greenberg E, Yorke ED, Lovelock DM, Hunt MA, Rosenzweig KE (2008) Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who’s at risk? Int J Radiat Oncol Biol Phys 72(5):1283–1286PubMedCrossRefGoogle Scholar
  13. Ishiyama H, Teh BS, Lo SS, Mathews T, Blanco A, Amato R, Ellis RJ, Mayr NA, Paulino AC, Xu B, Butler BE (2011) Stereotactic body radiation therapy for prostate cancer. Future Oncol 7(9):1077–1086. doi: 10.2217/fon.11.86 PubMedCrossRefGoogle Scholar
  14. Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA (2004) Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58(4):1017–1021PubMedCrossRefGoogle Scholar
  15. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP (2005) Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63(2):320–323PubMedCrossRefGoogle Scholar
  16. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA (2009a) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27(10):1585–1591CrossRefGoogle Scholar
  17. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX (2009b) Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114(3):589–595CrossRefGoogle Scholar
  18. Lo SS, Cardenes HR, Teh BS, Fakiris AJ, Henderson MA, Papiez L, McGarry RC, Wang JZ, Li K, Mayr NA, Timmerman RD (2008) Stereotactic body radiation therapy for nonpulmonary primary tumors. Expert Rev Anticancer Ther 8(12):1939–1951PubMedCrossRefGoogle Scholar
  19. Lo SS, Fakiris AJ, Teh BS, Cardenes HR, Henderson MA, Forquer JA, Papiez L, McGarry RC, Wang JZ, Li K, Mayr NA, Timmerman RD (2009) Stereotactic body radiation therapy for oligometastases. Expert Rev Anticancer Ther 9(5):621–635PubMedCrossRefGoogle Scholar
  20. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, Teh BS, McGarry RC, Cardenes HR, Timmerman RD (2010a) Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 7(1):44–54CrossRefGoogle Scholar
  21. Lo SS, Teh BS, Mayr NA, Olencki TE, Wang JZ, Grecula JC, Lu JJ, Timmerman RD (2010b) Stereotactic body radiation therapy for oligometastases. Discov Med 10(52):247–254Google Scholar
  22. Mayr NA, Huang Z, Sohn JW, Lo SS, Teh BS, Lu JJ, Grecula JC, Kunos C (2011) Emerging application of stereotactic body radiation therapy for gynecologic malignancies. Expert Rev Anticancer Ther 11(7):1069–1075. doi: 10.1586/era.11.81 PubMedCrossRefGoogle Scholar
  23. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, Okunieff P (2008) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112(3):650–658PubMedCrossRefGoogle Scholar
  24. Park C, Papiez L, Zhang S, Story M, Timmerman RD (2008) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70(3):847–852PubMedCrossRefGoogle Scholar
  25. Rose PS, Laufer I, Boland PJ, Hanover A, Bilsky MH, Yamada J, Lis E (2009) Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 27(30):5075–5079. JCO.2008.19.3508[pii], doi: 10.1200/JCO.2008.19.3508 Google Scholar
  26. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE (2009a) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572–1578CrossRefGoogle Scholar
  27. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE (2009b) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27(10):1579–1584CrossRefGoogle Scholar
  28. Sahgal A, Ma L, Gibbs I, Gerszten PC, Ryu S, Soltys S, Weinberg V, Wong S, Chang E, Fowler J, Larson DA (2010a) Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 77(2):548–553. S0360-3016(09)00772-X[pii], doi: 10.1016/j.ijrobp.2009.05.023 Google Scholar
  29. Sahgal A, Ma L, Weinberg V, Gibbs IC, Chao S, Chang UK, Werner-Wasik M, Angelov L, Chang EL, Sohn MJ, Soltys SG, Letourneau D, Ryu S, Gerszten PC, Fowler J, Wong CS, Larson DA (2010b) Reirradiation HUMAN spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. S0360-3016(10)03067-1[pii], doi: 10.1016/j.ijrobp.2010.08.021
  30. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR (2008) An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 14(16):5255–5259PubMedCrossRefGoogle Scholar
  31. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC (2008) Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72(3):678–686PubMedCrossRefGoogle Scholar
  32. Shirato H, Shimizu S, Shimizu T, Nishioka T, Miyasaka K (1999) Real-time tumour-tracking radiotherapy. Lancet 353(9161):1331–1332. S0140-6736(99)00700-X[pii], doi: 10.1016/S0140-6736(99)00700-X Google Scholar
  33. Siddiqui F, Raben D, Lu JJ, Grecula JC, Lo SS, Huang Z, Mayr NA, Teh BS, Yao M (2011) Emerging applications of stereotactic body radiation therapy for head and neck cancer. Expert Rev Anticancer Ther 11(9):1429–1436. doi: 10.1586/era.11.110 PubMedCrossRefGoogle Scholar
  34. Svedman C, Sandstrom P, Pisa P, Blomgren H, Lax I, Kalkner KM, Nilsson S, Wersall P (2006) A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45(7):870–875PubMedCrossRefGoogle Scholar
  35. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24(30):4833–4839. 24/30/4833[pii], doi: 10.1200/JCO.2006.07.5937 Google Scholar
  36. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070–1076. 303/11/1070[pii], doi: 10.1001/jama.2010.261 Google Scholar
  37. Timmerman RD, Kavanagh BD (2005) Stereotactic body radiation therapy. Curr Probl Cancer 29(3):120–157PubMedCrossRefGoogle Scholar
  38. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L (2007) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25(8):947–952PubMedCrossRefGoogle Scholar
  39. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26(4):657–664PubMedCrossRefGoogle Scholar
  40. Uematsu M, Shioda A, Tahara K, Fukui T, Yamamoto F, Tsumatori G, Ozeki Y, Aoki T, Watanabe M, Kusano S (1998) Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 82(6):1062–1070PubMedCrossRefGoogle Scholar
  41. Wang JZ, Huang Z, Lo SS, Yuh WT, Mayr NA (2010) A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med 2(39):39ra48. 2/39/39ra48[pii], doi: 10.1126/scitranslmed.3000864
  42. Wolbarst AB, Chin LM, Svensson GK (1982) Optimization of radiation therapy: integral-response of a model biological system. Int J Radiat Oncol Biol Phys 8(10):1761–1769PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Simon S. Lo
    • 1
  • Bin S. Teh
    • 2
  • Jiade J. Lu
    • 3
  • Tracey E. Schefter
    • 4
  1. 1.Department of Radiation OncologyUniversity Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve UniversityClevelandUSA
  2. 2.Department of Radiation Oncology, The Methodist Hospital Cancer Center and Research InstituteWeill Cornell Medical CollegeHoustonUSA
  3. 3.Department of Radiation Oncology, National University Cancer Institute of SingaporeNational University of SingaporeSingaporeSingapore
  4. 4.Department of Radiation OncologyUniversity of Colorado DenverAuroraUSA

Personalised recommendations